Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

470 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients.
Robert C, Long GV, Larkin J, Wolchok JD, Hassel JC, Schadendorf D, Hodi FS, Lebbé C, Grob JJ, Hyngstrom JR, Wagstaff J, Chesney J, Butler MO, Bechter O, Márquez-Rodas I, Pavlick AC, Durani P, Pe Benito M, Wang P, Postow MA, Ascierto PA. Robert C, et al. Among authors: wolchok jd. Eur J Cancer. 2025 Jan;214:115119. doi: 10.1016/j.ejca.2024.115119. Epub 2024 Nov 16. Eur J Cancer. 2025. PMID: 39612757 Free article.
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects.
Ertl C, Ruf T, Mentzer D, Kong M, Kramer R, Bergwelt-Baildon MV, Subklewe M, Tomsitz D, Ascierto PA, Dummer R, Gogas H, Lebbé C, Long GV, McArthur G, Neilan TG, Ribas A, Robert C, Schadendorf D, Zimmer L, Eigentler T, Grabbe S, Forschner A, Kähler KC, Milani V, Pföhler C, Hassel J, Gutzmer R, Loquai C, Routy B, Furness AJS, Blank C, Wolchok JD, French LE, Hauschild A, Heinzerling L. Ertl C, et al. Among authors: wolchok jd. Eur J Cancer. 2024 Mar;199:113505. doi: 10.1016/j.ejca.2023.113505. Epub 2023 Dec 23. Eur J Cancer. 2024. PMID: 38262306
RECISTv1.1 progression in oncology: Shades of gray.
Topp B, Snyder A, Wolchok J. Topp B, et al. Cancer Cell. 2023 Jun 12;41(6):1003-1005. doi: 10.1016/j.ccell.2023.04.012. Epub 2023 May 11. Cancer Cell. 2023. PMID: 37172579 Free article.
Concurrent SOS1 and MEK suppression inhibits signaling and growth of NF1-null melanoma.
Marasco M, Kumar D, Seale T, Borrego SG, Kaplun E, Aricescu I, Cole S, Qeriqi B, Qiu J, Chen X, Bahr A, Fidele D, Hofmann MH, Gerlach D, Savarese F, Merghoub T, Wolchok JD, Yao Z, de Stanchina E, Solit D, Misale S, Rosen N. Marasco M, et al. Among authors: wolchok jd. Cell Rep Med. 2024 Nov 19;5(11):101818. doi: 10.1016/j.xcrm.2024.101818. Epub 2024 Nov 1. Cell Rep Med. 2024. PMID: 39488215 Free PMC article.
TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models.
Hackett CS, Hirschhorn D, Tang MS, Purdon TJ, Marouf Y, Piersigilli A, Agaram NP, Liu C, Schad SE, de Stanchina E, Rafiq S, Monette S, Wolchok JD, Merghoub T, Brentjens RJ. Hackett CS, et al. Among authors: wolchok jd. Mol Ther Oncol. 2024 Aug 22;32(3):200862. doi: 10.1016/j.omton.2024.200862. eCollection 2024 Sep 19. Mol Ther Oncol. 2024. PMID: 39308793 Free PMC article.
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, Queirolo P, Dummer R, Butler MO, Hill AG, Postow MA, Gaudy-Marqueste C, Medina T, Lao CD, Walker J, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Sandhu S, Lebbé C, Ascierto PA, Long GV, Ritchings C, Nassar A, Askelson M, Benito MP, Wang W, Hodi FS, Larkin J; CheckMate 067 Investigators. Wolchok JD, et al. N Engl J Med. 2025 Jan 2;392(1):11-22. doi: 10.1056/NEJMoa2407417. Epub 2024 Sep 15. N Engl J Med. 2025. PMID: 39282897 Clinical Trial.
470 results